Moberg Pharma and Karo Healthcare have announced an expansion of their licensing agreement for MOB-015 (Terclara®), now including Australia, New Zealand, South Korea, and Taiwan. By leveraging Karo’s established infrastructure in these regions, Moberg secures a high-authority entry point into markets with a total population of 100m people, further de-risking the global roll-out.
LÄS MER
